Evidence map›Paper›PMID 38323273›Full record

ArticleAmerican journal of cancer research2024

Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation.

Yuan-Chin Tsai, Shu-Pin Huang, Wei-Chung Cheng, Yu-Ching Fan, Ya-Ching Lin, Shin-Yu Tsai, Chao-Yuan Huang, Chia-Cheng Yu, Victor C Lin, Jiun-Hung Geng and 3 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuan-Chin TsaiGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.
Shu-Pin HuangDepartment of Urology, Kaohsiung Medical University Hospital Kaohsiung 807, Taiwan.
Wei-Chung ChengPh.D. Program for Cancer Biology and Drug Discovery, Cancer Biology and Precision Therapeutics Center, China Medical University Taichung 404, Taiwan.
Yu-Ching FanPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica Taipei 110, Taiwan.
Ya-Ching LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.
Shin-Yu TsaiGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University Taipei 100, Taiwan.
Chia-Cheng YuDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Kaohsiung 813, Taiwan.
Victor C LinDepartment of Urology, E-Da Hospital Kaohsiung 824, Taiwan.
Jiun-Hung GengDepartment of Urology, Kaohsiung Medical University Hospital Kaohsiung 807, Taiwan.
Chia-Yang LiGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung 807, Taiwan.
Te-Ling LuDepartment of Pharmacy, China Medical University Taichung 406, Taiwan.
Bo-Ying BaoDepartment of Pharmacy, China Medical University Taichung 406, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One-carbon metabolism plays a crucial role in tumorigenesis as it supplies the one-carbon units necessary for nucleotide synthesis, epigenetic regulation, and redox metabolism, ensuring the rapid proliferation of cancer cells. However, their roles in prostate cancer progression remain poorly understood. In this study, we investigated the association between genetic variants in the one-carbon metabolism pathway and clinical outcomes in patients receiving androgen deprivation therapy for prostate cancer. The associations of 130 single-nucleotide polymorphisms located within 14 genes involved in the one-carbon metabolism pathway with cancer-specific survival (CSS), overall survival, and progression-free survival were assessed using Cox regression in 630 patients with prostate cancer. Subsequently, functional studies were performed using prostate cancer cell lines. After adjusting for covariates and multiple testing,

Indexed as

cell cycleMTHFD1LOne-carbon metabolismprostate cancerRNA sequencingsurvival

Identifiers

PMID38323273
PMCPMC10839318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.